Kazia Therapeutics (KZIA) Income towards Parent Company (2009 - 2017)

Kazia Therapeutics (KZIA) has 9 years of Income towards Parent Company data on file, last reported at -$8.0 million in Q2 2017.

• Quarterly Income towards Parent Company rose 11.01% year-over-year to -$8.0 million in Q2 2017, while the trailing twelve-month figure through Dec 2018 was -$8.0 million (up 69.25% YoY) and the FY2025 annual result came in at -$13.3 million, up 24.87% from the prior year.
• Income towards Parent Company improved to -$8.0 million in Q2 2017, from -$9.0 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$5.1 million in Q4 2015 to a low of -$3055.3 billion in Q4 2013.
• A 5-year average of -$509.2 billion and a median of -$8.5 million in 2016 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2014 — Income towards Parent Company surged 100.0% — and 2016, when it slumped 76.11%.
• Tracing KZIA's Income towards Parent Company over 5 years: stood at -$3055.3 billion in 2013, then surged by 100.0% to -$6.4 million in 2014, then gained by 19.57% to -$5.1 million in 2015, then tumbled by 76.11% to -$9.0 million in 2016, then gained by 11.42% to -$8.0 million in 2017.
• The last three Income towards Parent Company figures came in at -$8.0 million (Q2 2017), -$9.0 million (Q4 2016), and -$9.0 million (Q2 2016), per Business Quant data.